SCHEMBL19458977

SCHEMBL19458977

OC1(c2ccccc2)C[CH]C1

nearest known ligand 0.47

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ OPRL1 P41146 14/20 0.47
▸ OPRM1 P35372 9/20 0.47
▸ OPRK1 P41145 7/20 0.47
▸ OPRD1 P41143 5/20 0.42
▸ POLB P06746 1/20 0.41
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.38
▸ HDAC4 P56524 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28524217 0.84 OPRL1 (0.47) OPRL1OPRM1OPRK1OPRD1POLB
SCHEMBL34468465 0.78 OPRL1 (0.50) OPRL1OPRM1OPRK1OPRD1POLB
SCHEMBL10060840 0.78 OPRL1 (0.68) OPRL1OPRM1OPRK1OPRD1POLB
SCHEMBL7815717 0.78 OPRL1 (0.68) OPRL1OPRM1OPRK1OPRD1POLB
SCHEMBL7811311 0.75 OPRL1 (0.53) OPRL1OPRM1OPRK1OPRD1POLB
SCHEMBL1724862 0.74 OPRL1 (0.57) OPRL1OPRM1OPRK1OPRD1POLB
SCHEMBL1109741 0.74 OPRL1 (0.57) OPRL1OPRM1OPRK1OPRD1POLB
SCHEMBL42581 0.73 OPRL1 (0.52) OPRL1OPRM1OPRK1OPRD1POLB
SCHEMBL28243555 0.72 OPRM1 (0.48) OPRL1OPRM1OPRK1
SCHEMBL16823462 0.72 OPRL1 (0.45) OPRL1OPRM1OPRK1OPRD1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 — — EP claimed
CN-109311889-B Activin receptor-like kinase inhibitors 缆图药品公司 2021-11-16 — — CN claimed
EP-3442977-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2019-02-20 — — EP claimed
CN-109311889-A Activin receptor-like kinase inhibitors 蓝图药品公司 2019-02-05 — — CN claimed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 — — WO claimed
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2024-05-16 — — US disclosed
EP-4285996-A2 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2023-12-06 — — EP disclosed
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 — — EP disclosed
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 — — US disclosed
CN-109311889-B Activin receptor-like kinase inhibitors 缆图药品公司 2021-11-16 — — CN disclosed
US-10669277-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2020-06-02 — — US disclosed
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2020-01-30 — — US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 — — US disclosed
EP-3442977-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2019-02-20 — — EP disclosed
CN-109311889-A Activin receptor-like kinase inhibitors 蓝图药品公司 2019-02-05 — — CN disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 — — WO disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669277-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 OPRL1 2888/4885OPRM1 2829/4885OPRK1 1945/4885
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 OPRL1 2888/4885OPRM1 2829/4885OPRK1 1945/4885
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 OPRL1 2888/4885OPRM1 2829/4885OPRK1 1945/4885
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 OPRL1 2888/4885OPRM1 2829/4885OPRK1 1945/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 OPRL1 2433/4885OPRM1 2084/4885OPRK1 1601/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 OPRL1 2888/4885OPRM1 2829/4885OPRK1 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback